A retrospective study of EUS-TA for resectable pancreatic body and tail cancer

A retrospective study of EUS-TA with rapid on-site evaluation to minimize the number of punctures in resectable pancreatic body and tail cancer - A retrospective study of EUS-TA with rapid on-site evaluation to minimize the number of punctures in resectable pancreatic body and tail cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057987

Enrollment

130

Registered

2025-05-27

Start date

2025-04-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable pancreatic body and tail cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent EUS-TA for resectable pancreatic body and tail cancer with planned surgical resection at the time of EUS-TA, and a final pathological diagnosis of invasive pancreatic ductal adenocarcinoma.

Exclusion criteria

Exclusion criteria: 1) Patients in whom EUS-TA was performed without clearly visualizing the pancreatic mass 2) Patients in whom invasive pancreatic ductal carcinoma was not suspected at the time of EUS-TA 3) Patients in whom EUS-TA was performed on metastatic lymph nodes 4) Patients with unavailable or undocumented EUS-TA findings or pathological diagnosis details

Design outcomes

Primary

Measure	Time frame
technical success rate of EUS-TA, accuracy rate of EUS-TA, concordance rate between ROSE and final cytological diagnoses	—

Countries

Japan

Contacts

Public ContactToji Murabayashi

Ise Red Cross Hospital Department of Gastroenterology

murabayashitoji@m2.gmobb.jp0596-28-2171

Outcome results